{"id":3884,"date":"2021-09-20T15:28:29","date_gmt":"2021-09-20T14:28:29","guid":{"rendered":"https:\/\/med.st-andrews.ac.uk\/tbtrials\/?page_id=3884"},"modified":"2025-03-24T11:39:18","modified_gmt":"2025-03-24T11:39:18","slug":"stand","status":"publish","type":"page","link":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/stand\/","title":{"rendered":"STAND"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”RGBA(0,0,0,0)” width=”100%” custom_margin=”180px||||false|false” custom_padding=”0px|||||” custom_css_main_element=”box-shadow:none!important;” global_colors_info=”{}”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Shorter Treatments by Advancing Novel Drugs<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

The Shortening Treatment by Advancing Novel Drugs (STAND) trial is a phase 3 open-label partially randomised clinical trial investigating the treatment shortening effect of a new regimen PaMZ<\/strong>. The study was funded by TB Alliance<\/a> and tested the safety, tolerability, and efficacy of regimen pretomanid (PA-824), moxifloxacin (M), and pyrazinamide (Z) based combinational TB therapy.<\/p>\n

PaMZ was the first drug regimen designed to treat both drugs-susceptible and -resistant TB and be compatible with anti-retroviral therapy.<\/p>\n

Nevertheless, all of the participants of the study were followed as per the protocol even after the enrolment ceased. Patients completed treatment and a six month follow up as well as additional monitoring for two years (Source TB Alliance<\/a>)<\/p>\n

STAND was paused in late 2015 by which time 284 patients had been enrolled. The study was eventually not re-started due to another trial testing BPaMZ regimen, which appeared to be more promising than the PaMZ regimen.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2021\/11\/STAND-01.jpg” title_text=”STAND-01″ _builder_version=”4.16″ _module_preset=”default” transform_scale=”83%|83%” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Shorter Treatments by Advancing Novel DrugsThe Shortening Treatment by Advancing Novel Drugs (STAND) trial is a phase 3 open-label partially randomised clinical trial investigating the treatment shortening effect of a new regimen PaMZ. The study was funded by TB Alliance and tested the safety, tolerability, and efficacy of regimen pretomanid (PA-824), moxifloxacin (M), and pyrazinamide […]<\/p>\n","protected":false},"author":157,"featured_media":0,"parent":3571,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-3884","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2026-06-07 16:32:24","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/3884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/users\/157"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/comments?post=3884"}],"version-history":[{"count":0,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/3884\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/3571"}],"wp:attachment":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/media?parent=3884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}